Title:
C18ORF54 PEPTIDES AND VACCINES INCLUDING THE SAME
Document Type and Number:
WIPO Patent Application WO/2012/053200
Kind Code:
A1
Abstract:
Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides or immunogenic fragments derived from SEQ ID NO: 35, that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) are provided. The amino acid sequences of the peptide of interest may be optionally modified with the substitution, deletion, insertion, or addition of one, two, or several amino acids sequences. Pharmaceutical compositions and methods of treating cancer that include such peptides are also provided.
More Like This:
Inventors:
NAKAMURA YUSUKE (JP)
TSUNODA TAKUYA (JP)
OSAWA RYUJI (JP)
YOSHIMURA SACHIKO (JP)
WATANABE TOMOHISA (JP)
TSUNODA TAKUYA (JP)
OSAWA RYUJI (JP)
YOSHIMURA SACHIKO (JP)
WATANABE TOMOHISA (JP)
Application Number:
PCT/JP2011/005844
Publication Date:
April 26, 2012
Filing Date:
October 19, 2011
Export Citation:
Assignee:
ONCOTHERAPY SCIENCE INC (JP)
NAKAMURA YUSUKE (JP)
TSUNODA TAKUYA (JP)
OSAWA RYUJI (JP)
YOSHIMURA SACHIKO (JP)
WATANABE TOMOHISA (JP)
NAKAMURA YUSUKE (JP)
TSUNODA TAKUYA (JP)
OSAWA RYUJI (JP)
YOSHIMURA SACHIKO (JP)
WATANABE TOMOHISA (JP)
International Classes:
C12N15/09; A61K38/00; A61K39/00; C07K7/06; C07K14/47
Domestic Patent References:
| WO2007013665A2 | 2007-02-01 | |||
| WO2008082730A2 | 2008-07-10 | |||
| WO2010108638A1 | 2010-09-30 | |||
| WO2004018667A1 | 2004-03-04 | |||
| WO2008154333A2 | 2008-12-18 |
Other References:
MIYAZAWA M. ET AL.: "Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer.", CANCER SCI., vol. 101, no. 2, February 2010 (2010-02-01), pages 433 - 439, XP055079367
YOKOMINE K. ET AL.: "The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy.", INT. J. CANCER, vol. 126, May 2010 (2010-05-01), pages 2153 - 2163, XP055083488
HARANO M. ET AL.: "HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.", INT. J. CANCER, vol. 123, 2008, pages 2616 - 2625, XP002602450
IMAI K. ET AL.: "Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.", CLIN. CANCER RES., vol. 14, no. 20, 2008, pages 6487 - 6495, XP055083490
SUDA T. ET AL.: "Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy.", CANCER SCI., vol. 98, 2007, pages 1803 - 1808, XP002476145
See also references of EP 2630237A4
YOKOMINE K. ET AL.: "The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy.", INT. J. CANCER, vol. 126, May 2010 (2010-05-01), pages 2153 - 2163, XP055083488
HARANO M. ET AL.: "HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.", INT. J. CANCER, vol. 123, 2008, pages 2616 - 2625, XP002602450
IMAI K. ET AL.: "Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.", CLIN. CANCER RES., vol. 14, no. 20, 2008, pages 6487 - 6495, XP055083490
SUDA T. ET AL.: "Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy.", CANCER SCI., vol. 98, 2007, pages 1803 - 1808, XP002476145
See also references of EP 2630237A4
Attorney, Agent or Firm:
SHIMIZU, Hatsushi et al. (1-1-1 Oroshi-machi, Tsuchiura-sh, Ibaraki 47, JP)
Download PDF:
Claims: